Review Article

Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues

Author(s): Jordan J. Feld*

Volume 18, Issue 7, 2017

Page: [851 - 862] Pages: 12

DOI: 10.2174/1389450116666150825111314

Price: $65


Treatment for hepatitis C virus (HCV) infection has progressed at remarkable speed. From poorly tolerated injectable therapy with very low cure rates, treatment has moved to highly effective well-tolerated all oral direct-acting antiviral therapies with cure rates above 90% for almost all patients populations. Direct-acting antivirals have developed out of an improved understanding of the viral lifecycle with recognition of targets that could be inhibited by small molecules. To date protease inhibitors, non-structural 5a inhibitors and nucleotide and non-nucleotide polymerase inhibitors have been developed. These agents have been used initially with peginterferon and ribavirin and subsequently in combination without the need for interferon. Rational combinations have overcome the major challenge of rapid emergence of drug resistance and second-generation agents in each class have improved safety and efficacy profiles with fewer drug-drug interactions and very few adverse effects. The progress of direct-acting antiviral development is outlined with a review of each class of agent as well as a discussion of challenges for the future.

Keywords: Direct-acting antivirals, resistance, cirrhosis, difficult-to-cure, hepatitis C virus.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy